Virbac reports 7.4% organic revenue growth in H1 2026

Virbac reported strong financial results for the first half of 2026, achieving organic revenue growth of 7.4% and an adjusted EBIT margin of 18.8% at CERS. Growth was observed across both primary segments, with companion animals increasing by 10.0% and farm animals by 6.7%.

Key drivers included a 12% increase in Supercharge platforms (excluding Thyronorm), a volume/mix effect of approximately 5.4%, and a price increase of about 2%. Consolidated net income rose by 5.9% to €87.1 million. While net debt increased to €196 million due to working capital seasonality, the company confirmed its 2026 guidance at the upper end of its initial range.

CEO Paul Martingell stated that the performance reflects the scaling of the company’s Supercharge platforms and the integration of Thyronorm, noting that the firm remains on track with its ‘Growing Together’ 2030 strategy.